Carregant...
Novel orally active selective progesterone receptor modulator CP8947 inhibits leiomyoma cell proliferation without adversely affecting endometrium or myometrium
CONTEXT: Uterine leiomyomas are highly prevalent and often symptomatic. Current medical therapies are limited. A novel, potent, selective, orally active therapy is needed. OBJECTIVE AND METHODS: To determine the progesterone receptor (PR) specificity and activation, endometrial response, and impact...
Guardat en:
| Autors principals: | , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2010
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3576019/ https://ncbi.nlm.nih.gov/pubmed/20493256 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jsbmb.2010.05.005 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|